News
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...
PatientPay, the leading patient payments partner for acute, ambulatory and specialty care, today announced its partnership with Neolytix, a premier healthcare management services organization (MSO).
Morningmate, the AI-powered all-in-one collaboration platform, is excited to announce the launch of its Global Partner Program, inviting businesses and technology providers worldwide to join forces in ...
Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...
Omeros (NASDAQ:OMER – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect Omeros to post earnings of ($0.71) per share ...
Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company’s shares opened today at ...
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, expectations were $-0.77556. Operator ...
Catherine Melfi; Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer; Omeros Corp Nadia Dac; Vice President, Chief Commercial Officer; Omeros Corp Good afternoon ...
Income from Discontinued Operations (Q4 2024): $5.2 million. Omeros Corp (NASDAQ:OMER) has resubmitted its Biologics License Application (BLA) for narsoplimab in the treatment of TA-TMA, with a PDUFA ...
SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share. Losses, ...
SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results